Presight Sensei Co-Invest Fund, L.P. and 3 Others Sells $5.44M of Sensei Biotherapeutics Inc (SNSE) — SEC Form 4, Jun 02, 2023

Open-Market Net Sale · SEC Form 4
−$5,437,824

Equity position changed by -100.0%

Reporting Owners
Presight Sensei Co-Invest Fund, L.P.
Other
Apeiron Investment Group Ltd.
10%+
Christian Angermayer
10%+

+ 1 more

TXN 2023-06-01 · FILED 2023-06-02
Equity Position 0 sh 3,441,661 → 0
Equity Change -100.0% shares held after vs before
Filing Lag 1 business day within 2-day SEC deadline
Form 4 · Statement of Changes in Beneficial Ownership

Sensei Biotherapeutics Inc

SNSE CIK 0001829802
All Sensei Biotherapeutics Inc insider activity
Filing Date
2023-06-02
Report Date
2023-06-01
Accession No.
0000921895-23-001420
Accepted At
2023-06-02 21:03 UTC
Reporting Owners
Name Relationship
Presight Sensei Co-Invest Fund, L.P. CIK 0001828422
See Explanation of Responses
Apeiron Investment Group Ltd. CIK 0001845711
10% Owner
Christian Angermayer CIK 0001845872
10% Owner
Presight Co-Invest Management, L.L.C. CIK 0001846009
See Explanation of Responses
Presight Sensei Co-Invest Fund, L.P. at Sensei Biotherapeutics Inc Full insider history
Bought (12 mo) —
Sold (12 mo) —
More from this insider at Sensei Biotherapeutics Inc
2023-02-27 Buy +$3,539 View
All filings by this insider at Sensei Biotherapeutics Inc
Non-Derivative Securities Transactions
Title Date Type Shares Price Net Total Post-Txn Ownership
Common StockF1F2 2023-06-01 S - Sale 2,485,923 D $1.58 -$3,927,758 0 Indirect
Common StockF1F3 2023-06-01 S - Sale 955,738 D $1.58 -$1,510,066 0 Indirect
Footnotes (3)
F1
This Form 4 is filed jointly by Apeiron Investment Group Ltd. ("Apeiron"), Christian Angermayer, Presight Sensei Co-Invest Fund, L.P. ("Presight Co-Invest") and Presight Sensei Co-Invest Management, L.L.C. ("Presight Co-Invest Management", and collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that previously beneficially owned over 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein. Show more
F2
Securities owned directly by Apeiron. Mr. Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities owned directly by Apeiron. Show more
F3
Securities owned directly by Presight Co-Invest. As the general partner of Presight Co-Invest, Presight Co-Invest Management may be deemed to beneficially own the securities owned directly by Presight Co-Invest. As the sole member of Presight Co-Invest Management, Apeiron may be deemed to beneficially own the securities owned directly by Presight Co-Invest. Mr. Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities owned directly by Presight Co-Invest. Show more

Related filings at Sensei Biotherapeutics Inc

Institutional Holders
13F holders · Jun 30, 2026 45 institutional managers reporting a position
Largest by reported value
  1. Suvretta Capital Management, Llc $50.5M
  2. Avoro Capital Advisors Llc $36.1M
  3. Baker Bros. Advisors Lp $32.2M
5%+ Holders · 13D/G 3 filers

Latest Schedule 13D/G per filer; stakes the filer reported closed are left out.

Other insiders at Sensei Biotherapeutics Inc
All Sensei Biotherapeutics Inc insider activity
GET /v1/forms/4/0000921895-23-001420 API docs
View Original SEC Filing